No improvement in long-term survival over time for chronic lymphocytic leukemia patients in stereotyped subsets #1 and #2 treated with chemo(immuno)therapy
暂无分享,去创建一个
K. Stamatopoulos | N. Darzentas | T. Shanafelt | Xiao-Jie Yan | N. Chiorazzi | G. Juliusson | R. Rosenquist | V. Giudicelli | M. Lefranc | A. Langerak | Š. Pospíšilová | D. Oscier | Z. Davis | F. Davi | D. Jelinek | M. Catherwood | S. Veronese | F. Nguyen‐Khac | M. Montillo | L. Trentin | A. Anagnostopoulos | L. Mansouri | C. Niemann | K. Smedby | K. Plevova | P. Ghia | C. Belessi | N. Stavroyianni | A. Hadzidimitriou | P. Baliakas | A. Agathangelidis | E. Minga | L. Scarfò | Y. Sandberg | T. Tzenou | C. Chu | P. Panagiotidis | M. Mattsson | F. Vojdeman | L. Sutton | K. Plevová
[1] B. Nadel,et al. Genetic landscape and deregulated pathways in B‐cell lymphoid malignancies , 2017, Journal of internal medicine.
[2] K. Stamatopoulos,et al. Immunoglobulin gene sequence analysis in chronic lymphocytic leukemia: updated ERIC recommendations , 2017, Leukemia.
[3] S. O'brien,et al. Novel agents in chronic lymphocytic leukemia. , 2016, Hematology. American Society of Hematology. Education Program.
[4] K. Rostgaard,et al. Improved survival for patients diagnosed with chronic lymphocytic leukemia in the era of chemo-immunotherapy: a Danish population-based study of 10455 patients , 2016, Blood Cancer Journal.
[5] E. Campo,et al. Different spectra of recurrent gene mutations in subsets of chronic lymphocytic leukemia harboring stereotyped B-cell receptors , 2016, Haematologica.
[6] T. Haferlach,et al. Differences in prognosis of stereotyped IGHV3-21 chronic lymphocytic leukaemia according to additional molecular and cytogenetic aberrations , 2016, Leukemia.
[7] P. Kiewe,et al. Altered treatment of chronic lymphocytic leukemia in Germany during the last decade , 2016, Annals of Hematology.
[8] G. Fabbri,et al. The molecular pathogenesis of chronic lymphocytic leukaemia , 2016, Nature Reviews Cancer.
[9] F. Stingo,et al. Fludarabine, cyclophosphamide, and rituximab treatment achieves long-term disease-free survival in IGHV-mutated chronic lymphocytic leukemia. , 2016, Blood.
[10] H. Döhner,et al. Long-term remissions after FCR chemoimmunotherapy in previously untreated patients with CLL: updated results of the CLL8 trial. , 2016, Blood.
[11] R. Foà,et al. Molecular prediction of durable remission after first-line fludarabine-cyclophosphamide-rituximab in chronic lymphocytic leukemia. , 2015, Blood.
[12] M. Hallek. Chronic lymphocytic leukemia: 2015 Update on diagnosis, risk stratification, and treatment , 2015, American journal of hematology.
[13] Lefteris Angelis,et al. Not all IGHV3-21 chronic lymphocytic leukemias are equal: prognostic considerations. , 2015, Blood.
[14] Lefteris Angelis,et al. Clinical effect of stereotyped B-cell receptor immunoglobulins in chronic lymphocytic leukaemia: a retrospective multicentre study. , 2014, The Lancet. Haematology.
[15] Kostas Stamatopoulos,et al. Stereotyped B-cell receptors in one-third of chronic lymphocytic leukemia: a molecular classification with implications for targeted therapies. , 2012, Blood.
[16] A. Berrebi,et al. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial , 2010, The Lancet.